Key result
Intensive BP control to SBP ≤130 and RAS blockade reduce proteinuria and delay diabetic renal progression.
Why the study?
Does intensive blood pressure control and RAS blockade prevent renal injury and delay progression of renal disease in patients with diabetes and hypertension?
Does intensive blood pressure control and RAS blockade prevent renal injury and delay progression of renal disease in patients with diabetes and hypertension?
Intensive blood pressure control and the use of renin-angiotensin system blockers are crucial therapeutic strategies for preventing renal injury and delaying end-stage renal disease in diabetic patients.
May support intensive BP control plus RAS blockade to limit renal progression in diabetes; leaves open optimal targets in prospective trials.
Diabetes and hypertension are the leading causes of end-stage renal disease in the Western world. Inadequate control of both systemic and glomerular capillary pressure in diabetics results in increasing hydraulic force and mechanical stretch on the glomeruli, with a subsequent increase in proteinuria and ultimately glomerulosclerosis. Therapeutic strategies that combine systemic and glomerular capillary pressure reduction result in reduced proteinuria and are ideal for preventing renal injury. Both experimental and clinical studies have demonstrated the importance of intensive control of blood pressure, preferably to systolic blood pressure (SBP) < or =130 mm Hg to delay progression of renal disease. In particular, drugs that block the renin-angiotensin system (RAS) offer the advantage of consistently reducing glomerular capillary pressure and proteinuria relative to changes in systemic blood pressure. This combination of events is ideal for delaying progression of renal disease. However, the use of drugs that block the RAS is not a surrogate for maintaining tight control of blood pressure.
No takes yet. Share an insight, caveat, or question.
Matthew A. Weir (1999) conducted a review in Diabetes and hypertension. Intensive blood pressure control and RAS blockade was evaluated. Intensive blood pressure control (SBP ≤130 mm Hg) and renin-angiotensin system blockade are crucial for reducing proteinuria and delaying the progression of renal disease in diabetes and hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: